AP2013007180A0 - Truncated HIV envelope proteins (ENV), methods andcompositions related thereto - Google Patents

Truncated HIV envelope proteins (ENV), methods andcompositions related thereto

Info

Publication number
AP2013007180A0
AP2013007180A0 AP2013007180A AP2013007180A AP2013007180A0 AP 2013007180 A0 AP2013007180 A0 AP 2013007180A0 AP 2013007180 A AP2013007180 A AP 2013007180A AP 2013007180 A AP2013007180 A AP 2013007180A AP 2013007180 A0 AP2013007180 A0 AP 2013007180A0
Authority
AP
ARIPO
Prior art keywords
env
envelope proteins
hiv envelope
truncated hiv
andcompositions
Prior art date
Application number
AP2013007180A
Other languages
English (en)
Inventor
Carl Alving
Mangala Rao
Thomas C Vancott
Original Assignee
Advanced Bioscience Lab Inc
Jackson H M Found Military Med
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Bioscience Lab Inc, Jackson H M Found Military Med, Us Gov Health & Human Serv filed Critical Advanced Bioscience Lab Inc
Publication of AP2013007180A0 publication Critical patent/AP2013007180A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • C07K14/16—HIV-1 ; HIV-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
AP2013007180A 2011-04-25 2012-04-25 Truncated HIV envelope proteins (ENV), methods andcompositions related thereto AP2013007180A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161478857P 2011-04-25 2011-04-25
PCT/US2012/035026 WO2012149038A1 (fr) 2011-04-25 2012-04-25 Protéines tronquées d'enveloppe (env) du vih, procédés et compositions associés à celles-ci

Publications (1)

Publication Number Publication Date
AP2013007180A0 true AP2013007180A0 (en) 2013-10-31

Family

ID=46147686

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2013007180A AP2013007180A0 (en) 2011-04-25 2012-04-25 Truncated HIV envelope proteins (ENV), methods andcompositions related thereto

Country Status (10)

Country Link
US (1) US10081658B2 (fr)
EP (1) EP2701736A1 (fr)
JP (1) JP6407714B2 (fr)
KR (1) KR102007444B1 (fr)
CN (1) CN103945864A (fr)
AP (1) AP2013007180A0 (fr)
CA (1) CA2834288A1 (fr)
HK (1) HK1200329A1 (fr)
WO (1) WO2012149038A1 (fr)
ZA (1) ZA201307529B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2364314T3 (pl) 2008-12-09 2014-08-29 Gilead Sciences Inc Modulatory receptorów Toll-podobnych
US20160039885A1 (en) * 2013-04-02 2016-02-11 Duke University Recombinant production of hiv-1 envelope glycoproteins
KR102019572B1 (ko) * 2014-07-11 2019-09-06 길리애드 사이언시즈, 인코포레이티드 Hiv의 치료를 위한 톨-유사 수용체의 조정제
CN110305133A (zh) 2014-09-16 2019-10-08 吉利德科学公司 Toll样受体调节剂的固体形式
HUE045993T2 (hu) * 2015-12-15 2020-01-28 Janssen Vaccines & Prevention Bv Emberi immunhiány vírus antigének, vektorok, készítmények és alkalmazásukra szolgáló eljárások
US10696985B1 (en) * 2016-06-06 2020-06-30 Vanderbilt University Reversibly crosslinked endosomolytic polymer vesicles for cytosolic drug delivery
EP4076467A4 (fr) * 2019-11-04 2023-12-27 Decibel Therapeutics, Inc. Promoteurs de cellules de support vestibulaires et leurs utilisations

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4769331A (en) 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
IL84154A0 (en) 1986-10-16 1988-03-31 Microgenesys Inc Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
IL86724A (en) 1987-06-19 1995-01-24 Siska Diagnostics Inc Methods and kits for amplification and testing of nucleic acid sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
ATE92538T1 (de) 1988-01-21 1993-08-15 Genentech Inc Verstaerkung und nachweis von nukleinsaeuresequenzen.
CA1340807C (fr) 1988-02-24 1999-11-02 Lawrence T. Malek Procede d'amplification d'une sequence d'acide nucleique
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
EP0386185A1 (fr) 1988-07-29 1990-09-12 IntraCel Corporation Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo
CA2003300A1 (fr) 1988-11-21 1990-05-21 Franklin Volvovitz Cutireaction et trousse pour le depistage du sida
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
US5552143A (en) 1989-03-24 1996-09-03 The Wistar Institute Of Anatomy & Biology Recombinant cytomegalovirus vaccine
GB9001766D0 (en) 1990-01-25 1990-03-28 Univ Court Of The University O Vaccines
US5514375A (en) 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
ATE247163T1 (de) 1991-03-07 2003-08-15 Virogenetics Corp Gentechnologisch hergestellter stamm für impfstoffe
FR2676071B1 (fr) * 1991-05-02 1994-11-18 Transgene Sa Nouveau variant gp160 non-clivable, soluble, de forme hybride.
US5169766A (en) 1991-06-14 1992-12-08 Life Technologies, Inc. Amplification of nucleic acid molecules
US5668648A (en) 1991-11-26 1997-09-16 Kabushiki Kaisha Toshiba Computer-assisted holographic display apparatus
US5650398A (en) 1992-07-02 1997-07-22 Cambridge Biotech Corporation Drug delivery enhancement via modified saponins
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
WO1995011995A1 (fr) 1993-10-26 1995-05-04 Affymax Technologies N.V. Reseaux de sondes d'acide nucleique sur des microplaquettes biologiques
US6485729B1 (en) 1993-09-13 2002-11-26 Protein Sciences Corporation Neuraminidase-supplemented compositions
US5654419A (en) 1994-02-01 1997-08-05 The Regents Of The University Of California Fluorescent labels and their use in separations
US5869255A (en) 1994-02-01 1999-02-09 The Regents Of The University Of California Probes labeled with energy transfer couples dyes exemplified with DNA fragment analysis
US5795716A (en) 1994-10-21 1998-08-18 Chee; Mark S. Computer-aided visualization and analysis system for sequence evaluation
HU221204B1 (en) 1994-12-24 2002-08-28 Univ Cambridge Tech Use of nucleic acid for production of pharmaceuticals with tranfecting effect of nucleic acid on female mammals reproductive tract
FR2728795B1 (fr) 1994-12-30 1997-03-21 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5728528A (en) 1995-09-20 1998-03-17 The Regents Of The University Of California Universal spacer/energy transfer dyes
FR2741806B1 (fr) 1995-11-30 1998-02-20 Rhone Merieux Vaccin vivant recombinant a base d'herpesvirus felin de type 1, notamment contre la peritonite infectieuse feline
WO1997029212A1 (fr) 1996-02-08 1997-08-14 Affymetrix, Inc. Speciation de micro-organismes a partir de microplaquettes et caracterisation des phenotypes de ceux-ci
FR2750866B1 (fr) 1996-06-27 1998-11-27 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
FR2750865B1 (fr) 1996-06-27 1998-12-04 Rhone Merieux Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2
US6090393A (en) 1996-07-03 2000-07-18 Merial Recombinant canine adenoviruses, method for making and uses thereof
FR2751228B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Vaccin polynucleotidique bovin pour voie intradermique
FR2751224B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
FR2751223B1 (fr) 1996-07-19 1998-12-04 Rhone Merieux Formule de vaccin polynucleotidique felin
FR2751225B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
FR2751229B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
FR2751226B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
US5853992A (en) 1996-10-04 1998-12-29 The Regents Of The University Of California Cyanine dyes with high-absorbance cross section as donor chromophores in energy transfer labels
NZ334860A (en) 1996-10-17 2001-02-23 Oxford Biomedica Ltd Retroviral vectors with one or more auxiliary genes vpr, vif, tat and nef to be absent; with evidence that if all auxiliary genes absent the transduction efficiency is greatest
US6231859B1 (en) 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
FR2757061B1 (fr) 1996-12-16 1999-03-26 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
FR2758986B1 (fr) 1997-01-31 1999-04-30 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
US6368603B1 (en) 1997-03-05 2002-04-09 Merial Limited Lyme combination compositions and uses
US6004777A (en) 1997-03-12 1999-12-21 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US20020136722A1 (en) 1997-06-18 2002-09-26 Heath Andrew William Vaccination method
US6348450B1 (en) 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
ATE435661T1 (de) 1997-08-29 2009-07-15 Antigenics Inc Adjuvant qs-21 enthaltende zusammensetzungen mit polysorbate oder cyclodextrin als hilfsmittel
US6391314B1 (en) 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
FR2781159B1 (fr) 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
US6224882B1 (en) 1997-11-07 2001-05-01 Protein Science Corp. Insect cells or fractions as adjuvant for antigens
CN1322137C (zh) 1997-12-22 2007-06-20 牛津生物医学（英国）有限公司 基于马传染性贫血病毒(eiav)的逆转录病毒载体
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US6103526A (en) 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
US6497883B1 (en) 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
WO2001095919A2 (fr) 2000-06-15 2001-12-20 The Governement Of The United States Of America, As Represented By The Secretary Departement Of Hea Lth And Human Services Virus recombinant non replicant exprimant gm-csf et utilisation de celui-ci pour ameliorer des reponses immunitaires
CN1561389A (zh) * 2001-07-25 2005-01-05 纽约大学 糖基神经酰胺作为用于抗传染病和癌症的疫苗的佐剂的用途
ATE519500T1 (de) * 2001-09-06 2011-08-15 Progenics Pharm Inc Mutanten von hüllglykoproteinen des human immunodeficiency virus und deren verwendung
IL160983A0 (en) 2001-09-24 2004-08-31 Imp College Innovations Ltd Use of pyy for preparation of a medicament for modification of feeding behavior
AU2007210396B2 (en) 2006-01-31 2011-09-29 Bexcore Inc. Production of a soluble native form of recombinant protein by the signal sequence and secretional enhancer
US20110064760A1 (en) 2009-08-14 2011-03-17 Cho Michael W Polypeptides comprising epitopes of hiv gp41 and methods of use

Also Published As

Publication number Publication date
JP2014513956A (ja) 2014-06-19
KR20140073465A (ko) 2014-06-16
CN103945864A (zh) 2014-07-23
US10081658B2 (en) 2018-09-25
CA2834288A1 (fr) 2012-11-01
EP2701736A1 (fr) 2014-03-05
WO2012149038A1 (fr) 2012-11-01
WO2012149038A9 (fr) 2019-10-03
HK1200329A1 (en) 2015-08-07
US20140220107A1 (en) 2014-08-07
KR102007444B1 (ko) 2019-08-06
JP6407714B2 (ja) 2018-10-17
ZA201307529B (en) 2014-06-25

Similar Documents

Publication Publication Date Title
AU2016202543A1 (en) Human immunodeficiency virus (hiv)-neutralizing antibodies
HK1212935A1 (zh) 廣譜中和抗 抗體
EP2611465A4 (fr) Anticorps neutralisants anti-virus de l'immunodéficience humaine (vih)
WO2013085550A3 (fr) Immunogènes v1v2
GB2511700B (en) Reusable envelope
EP2638072A4 (fr) Protéines de fusion pour une thérapie contre le vih
EP2542703A4 (fr) Nouvelle glycoprotéine d'enveloppe du vih-1
LT2408476T (lt) Žmogaus imunodeficito virusą (živ) neutralizuojantys antikūnai
HK1200329A1 (en) Truncated hiv envelope proteins (env), methods and compositions related thereto hiv (env)
IL222228A0 (en) Hiv vaccine
IL231132A0 (en) Viral cleaning methods
IL239152A0 (en) Biological mixture inactivated from viruses
ZA201307069B (en) Combined cell based gp96-ig-siv/hiv, recombinant gp120 protein vaccination for protection from siv/hiv
HK1200870A1 (en) Use of non-subtype b gag proteins for lentiviral packaging b gag
WO2013052095A3 (fr) Vaccin
EP2714778A4 (fr) Polymérisation par faisceau électronique pulsé, balayé
EP2542252A4 (fr) Fragments à base d'enveloppe du vih-1
PT2643460T (pt) Métodos, composições e kits para determinação do virus da imunodeficiência humana (vih)
IL231494A0 (en) Lentiviral genome without chimeric integration as components against hiv-1
ZA201105357B (en) Splitting gp41
EP2710024A4 (fr) Conjugués et analogues d'osw-1, et leurs utilisations
EP3068427A4 (fr) Vaccin adn env plus rappel avec protéine contre le vih-1
AP2011005854A0 (en) Novel GP41 antigens.
EP2912055A4 (fr) Protéines env synthétiques
AU2011900691A0 (en) Viral vector